Argonaut Therapeutics Announces Appointment of New Board Director Dr Chan Hee Park of JW Pharmaceutical Corporation

Oxford, UK, 21 January 2021 – Argonaut Therapeutics, a leading developer of novel cancer agents, announced the appointment of Dr Chan Hee Park to its Board of Directors, representing key investor, JW Pharmaceutical Corporation.  Dr Park is the Chief Technological Officer and Senior Vice President of JW Pharmaceutical Corporation. He has more than 25 years … Read more

Argonaut Therapeutics Announces Appointment of New Board Director Nick Dixon-Clegg OSI

Oxford, UK, 1 August 2020 – Argonaut Therapeutics, a leading developer of novel cancer agents, announced the appointment of Mr Nick Dixon-Clegg to its Board of Directors, representing key investor, Oxford Sciences Innovation.  Nick is a Principal at OSI and brings 10 years of experience across investing and corporate finance. Prior to joining OSI Nick … Read more

Argonaut Therapeutics Announces Successful Completion of Financing Round

The investment will advance Argonaut’s Therapeutics’ arginine methylation inhibitor drug candidate towards the clinic and enable continued expansion of its drug discovery pipeline. Oxford, UK, March 2019 – Argonaut Therapeutics, a leading developer of novel cancer therapies, announced that it has raised new capital in its latest financing round. The financing included new investors JW … Read more